NO934163L - HER4 human reseptor-tyrosinkinase - Google Patents

HER4 human reseptor-tyrosinkinase

Info

Publication number
NO934163L
NO934163L NO934163A NO934163A NO934163L NO 934163 L NO934163 L NO 934163L NO 934163 A NO934163 A NO 934163A NO 934163 A NO934163 A NO 934163A NO 934163 L NO934163 L NO 934163L
Authority
NO
Norway
Prior art keywords
her4
tyrosine kinase
receptor tyrosine
human receptor
her4 human
Prior art date
Application number
NO934163A
Other languages
English (en)
Other versions
NO934163D0 (no
Inventor
Gregory D Plowman
Jean-Michel Culouscou
Mohammed Shoyab
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of NO934163D0 publication Critical patent/NO934163D0/no
Publication of NO934163L publication Critical patent/NO934163L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Det omtales en reseptor-tyrosinkinase, HER4/ p180erbB4, som er beslektet med den epidermale vekst- faktorreseptor. En HER4 ligand som er i stand til å indusere cellulær differensiering av brystkreftceller omtales også. Som følge av ekspresjonen av HER4 i mange krefttyper hos mennesker og i visse vev av nevronal og muskulær opprinnelse er det frembrakt forskjellige diagnostiske og terapeutiske anvendelser av HER4-avledete og HER4-beslektede, biologiske preparater.
NO934163A 1992-11-24 1993-11-18 HER4 human reseptor-tyrosinkinase NO934163L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98116592A 1992-11-24 1992-11-24

Publications (2)

Publication Number Publication Date
NO934163D0 NO934163D0 (no) 1993-11-18
NO934163L true NO934163L (no) 1994-05-25

Family

ID=25528166

Family Applications (1)

Application Number Title Priority Date Filing Date
NO934163A NO934163L (no) 1992-11-24 1993-11-18 HER4 human reseptor-tyrosinkinase

Country Status (8)

Country Link
EP (1) EP0599274A1 (no)
JP (1) JPH07132084A (no)
AU (1) AU676502B2 (no)
CA (1) CA2103323A1 (no)
FI (1) FI935175A (no)
IL (1) IL107661A0 (no)
MX (1) MX9307317A (no)
NO (1) NO934163L (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
WO1996002644A1 (en) * 1994-07-20 1996-02-01 Genetics Institute, Inc. Mlk receptor tyrosine kinases
AU3963295A (en) * 1994-10-14 1996-05-06 Bristol-Myers Squibb Company Her4 human receptor tyrosine kinase
AUPM959894A0 (en) * 1994-11-22 1994-12-15 Crc For Biopharmaceutical Research Pty Ltd Fusion proteins with cytotoxic activity against cells overexpressing erbb2-4
US6465623B2 (en) 1995-05-02 2002-10-15 Garvan Institute Of Medical Research GDU, a novel signalling protein
AUPN274295A0 (en) * 1995-05-02 1995-05-25 Garvan Institute Of Medical Research GDU, a novel signalling protein
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
WO1998002541A1 (en) 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
US7371376B1 (en) 1996-10-18 2008-05-13 Genentech, Inc. Anti-ErbB2 antibodies
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
AU732027B2 (en) 1997-02-10 2001-04-12 Genentech Inc. Heregulin variants
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
EP1941905A1 (en) 1998-03-27 2008-07-09 Genentech, Inc. APO-2 Ligand-anti-her-2 antibody synergism
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
US7041292B1 (en) 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
IL147241A0 (en) 1999-06-25 2002-08-14 Genentech Inc METHODS OF TREATMENT USING ANTI ErbB ANTIBODY-MAYTANSINOID CONJUGATES
AT500848B1 (de) 1999-06-25 2008-01-15 Genentech Inc Humanisierte anti-erbb2-antikörper
DK1242060T3 (da) * 1999-08-17 2006-08-21 Purdue Research Foundation Behandling af metastatisk sygdom
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
BR0013814A (pt) 1999-08-27 2002-04-23 Genentech Inc Métodos de tratamentos de um paciente humano suscetìvel a ou diagnosticado com uma doença com anticorpos anti-erbb2, artigos industrializados, métodos de tratamentos de câncer em pacientes humanos e usos do anticorpo anti-erbb2
AU2001247616B2 (en) 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
NZ522444A (en) 2000-05-19 2004-09-24 Genentech Inc Gene detection assay for improving the likelihood of an effective response to an ErbB antagonist cancer therapy
US6255111B1 (en) 2000-07-31 2001-07-03 Isis Pharmaceuticals, Inc. Antisense modulation of Her-4 expression
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
CA2490758C (en) 2002-07-15 2014-09-23 Genentech, Inc. Dosage form of recombinant humanized monoclonal antibody 2c4
JP5020636B2 (ja) 2003-11-06 2012-09-05 シアトル ジェネティックス， インコーポレイテッド リガンドに結合体化可能なモノメチルバリン化合物
JP4969440B2 (ja) 2004-04-08 2012-07-04 デビッド， ビー． エイガス， 疼痛治療のためのＥｒｂＢアンタゴニスト
EP2286844A3 (en) 2004-06-01 2012-08-22 Genentech, Inc. Antibody-drug conjugates and methods
CN101065151B (zh) 2004-09-23 2014-12-10 健泰科生物技术公司 半胱氨酸改造的抗体和偶联物
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US7939267B2 (en) 2004-11-04 2011-05-10 Laboratory Corporation Of America Holdings Detection of activation of endothelial cells as surrogate marker for angiogenesis
KR20180080371A (ko) 2005-01-21 2018-07-11 제넨테크, 인크. Ｈｅｒ 항체의 고정 용량 투여법
SI1850874T1 (sl) 2005-02-23 2014-01-31 Genentech, Inc. Podaljšanje časa za napredovanje bolezni ali za preživetje pri pacientkah z rakom na jajčnikih ob uporabi pertuzumaba
WO2008019290A2 (en) 2006-08-04 2008-02-14 Astrazeneca Ab Human antibodies to erbb 2
ES2477497T3 (es) 2007-03-02 2014-07-17 Genentech, Inc. Predicción de la respuesta a un inhibidor de la dimerización de HER basado en la expresión de HER3 bajo
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
TWI472339B (zh) 2008-01-30 2015-02-11 Genentech Inc 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
KR101789338B1 (ko) 2008-11-25 2017-10-23 제넨테크, 인크. 이소형 특이적 항-ｈｅｒ４ 항체
KR20150036824A (ko) 2009-03-20 2015-04-07 제넨테크, 인크. 이중특이적 항-ｈｅｒ 항체
US20120121586A1 (en) 2009-05-29 2012-05-17 Astrid Kiermaier Modulators for her2 signaling in her2 expressing patients with gastric cancer
EP2507381A4 (en) 2009-12-04 2016-07-20 Hoffmann La Roche PLURISPECIFIC ANTIBODIES, ANTIBODY ANALOGUES, COMPOSITIONS AND METHODS
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
KR102027011B1 (ko) 2010-08-20 2019-09-30 노파르티스 아게 표피 성장 인자 수용체 3 (ｈｅｒ3)에 대한 항체
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
WO2013033380A1 (en) 2011-08-31 2013-03-07 Genentech, Inc. Diagnostic markers
EP2764359B1 (en) 2011-10-04 2018-03-21 Expression Pathology, Inc. Srm/mrm assay for the receptor tyrosine-protein kinase erbb-4 protein (her4)
JP2015500638A (ja) 2011-11-30 2015-01-08 ジェネンテック， インコーポレイテッド 癌におけるｅｒｂｂ３変異
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
EP2788500A1 (en) 2011-12-09 2014-10-15 F.Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (ja) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Ｈｅｒ３阻害剤に関する診断及び治療
CN104813168B (zh) 2012-11-30 2017-10-20 霍夫曼-拉罗奇有限公司 需要pd‑l1抑制剂综合疗法的患者的鉴定
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
WO2016011167A1 (en) 2014-07-16 2016-01-21 Dana-Farber Cancer Institute, Inc., Et Al Her3 inhibition in low-grade serous ovarian cancers
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
EP3615695A1 (en) 2017-04-24 2020-03-04 Genentech, Inc. Erbb2/her2 mutations in the transmebrane or juxtamembrane domain
EP4180061A1 (en) 2021-11-10 2023-05-17 Nerviano Medical Sciences S.r.l. Anthracycline derivative linker reagents, antibody-drug conjugates and methods

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990014357A1 (en) * 1989-05-19 1990-11-29 Genentech, Inc. Her2 extracellular domain
EP0444961A1 (en) * 1990-03-02 1991-09-04 Bristol-Myers Squibb Company Her3: A novel EGF receptor homolog
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin

Also Published As

Publication number Publication date
JPH07132084A (ja) 1995-05-23
FI935175A (fi) 1994-05-25
MX9307317A (es) 1994-06-30
AU5180493A (en) 1994-06-09
EP0599274A1 (en) 1994-06-01
AU676502B2 (en) 1997-03-13
IL107661A0 (en) 1994-02-27
NO934163D0 (no) 1993-11-18
CA2103323A1 (en) 1994-05-25
FI935175A0 (fi) 1993-11-22

Similar Documents

Publication Publication Date Title
NO934163L (no) HER4 human reseptor-tyrosinkinase
CA2223016A1 (en) Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of her-2 autophosphorylation properties
NO995006L (no) Nye forbindelser
AP9901435A0 (en) Bicycle heteroaromatic compounds as protein tyrosine kinase inhibitors.
DK0836605T3 (da) Pyrrolopyrimidiner og fremgangsmåder til deres fremstilling
PT696205E (pt) Utilizacao de linhas celulares fetais nauro-derivadas para terapia de transplantacao
ATE343969T1 (de) Beschichtete medizinische geräte
CA2276180A1 (en) Method for activating human antigen-presenting cells, activated human antigen-presenting cells, and use thereof
YU49315B (sh) Inhibitor protein kinaze c, njegove farmaceutske formulacije i postupak za dobijanje
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69841481D1 (de) Verabreichung von arginin zur erwärmung von kaltem/kühlem gewebe
DE69738754D1 (de) Hemmer der interaktion zwischen p53 und mdm2
DE69426334T2 (de) Parenterales Busulfan zur Behandlung von malignen Krankheiten
NO971341D0 (no) Promoter for reseptor tyrosinkinase TIE
HUP0100012A2 (hu) Makrolid vegyületek alkalmazása rák és a makuláns elváltozások kezelésére
EP2005996A3 (en) Immunotherapeutic combination for the treatment of tumors
DK199881A (da) Analogifremgangsmaade til fremstilling af pharmakologisk aktive peptider
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
AU3401093A (en) Therapeutic agent for threatened abortion
HUP0302977A2 (hu) Daganatok és ezzel összefüggő fájdalmak kezelésére szolgáló endotelin antagonistákat tartalmazó gyógyszerkészítmény
DE69929616D1 (de) Oxyhuminsäure und ihre verwendung zur behandlung von verschiedenenen störungen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
MX9702664A (es) Tirosina cinasa receptora humana, her4 de la familia del receptor del factor del crecimiento epidermico.
TW374085B (en) Novel piperidine derivatives, their preparation, pharmaceutical formulation and medical use
Myothant et al. Primary Renal Care Part (I): Possible control of proteinuria and hematuria by the method of electrical stimulations through the acupuncture needles.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application